摘要
观察3-氢化松苓酸B(TAB)对宫颈癌U14的体内抑制作用,并初步判断其体内毒副作用,为3-氢化松苓酸B的利用提供依据.背部近腋窝处皮下接种0.2mL U14细胞(1×107个/mL)悬液制移植瘤模型,测定移植瘤体积,计算抑瘤率,观察组织形态;测定相关脏器指标,血液相关生化指标.结果表明3-氢化松苓酸B高、中、低剂量组可以显著降低移植瘤体积,抑瘤率分别为50.9%、36.8%、30.0%,阳性药雷帕霉素的抑瘤率为46.0%.3-氢化松苓酸B高、中、低剂量组均未对小鼠脏器组织形态产生明显影响.血液生化分析显示,TAB会降低血糖,对代谢可能产生一定影响,其他指标趋向正常,有待进一步研究.故TAB具有抑制U14细胞增殖的作用;治疗剂量下无明显毒副作用.
To observe the inhibitory effect of trametenolic acid B(TAB)on cervical cancer U14 in vivo,preliminarily evaluate its toxic and side effects,based on these results,explore its clinical application.Back near the armpit subcutaneous inoculation of 0.2 mL U14 cells(1×107/mL)suspension system will be transplanted tumor xenograft model,tumor volume,tumor inhibition rate was calculated to observe morphology;Determination of organ index,biochemical index of blood.The results show that the TAB groups(120,80 and 40 mg/kg)could significantly reduce the tumor volume and the tumor inhibition rate is50.9%,36.8%and 30%,the inhibitory rate of the positive drug rapamycin was 46.0%.Respectively,did not have a significant effect on the tissue morphology of the mice,blood biochemical analysis showed that TAB might have certain effects on metabolism,reduce blood sugar.Other indicators tend to be normal,which needed further study.The TAB has the effect of inhibiting the proliferation of U14 cells;there is no significant toxic and side effects at the treatment dose.
引文
[1]张爱笠,魏林珍,王海琳.宫颈癌与水通道蛋白关系的研究进展[J].医学综述,2015,21(24):4480-4482.
[2]王临虹,邱琇,郑睿敏,等.我国宫颈癌流行病学状况及防治策略的回顾与展望[J].中国妇幼卫生杂志,2010,1(3):146-149.
[3]欧幸甘,罗小平,覃秋萍.宫颈癌的新辅助化疗研究进展[J].中国医疗前沿,2010,5(18):14-16.
[4]王星琴,汪鋆植,郭志勇,等.大白栓菌中3-氢化松苓酸B含量的测定[J].三峡大学学报(自然科学版),2010,32(3):94-95,99.
[5]Turkistanli E C,Sogukpinar N,Saydam B K,et al.Cervical Cancer Prevention and Early Detection-the Role of Nurses and Midwives[J].Asian Pac J Cancer Prev,2003,4(1):15-21.
[6]汪鋆植,闫喜明,田华咏,等.以土家医三元论为指导的反选法在新药研究中的应用[J].中草药,2015,46(15):2189-2192.
[7]闫梅霞,关一鸣,胡清秀,等.硫磺菌菌丝体粗多糖对小鼠Lewis肺癌的体内抑制[J].食用菌学报,2011,18(1):46-48.